StockSignal
  • Screen for fundamentally interesting stocks
Sign in
Tandem Diabetes Care Inc. logo

Tandem Diabetes Care Inc.

TNDM · XNCM · Medical Devices · United States

Market Capitalization1.71B USD
Trailing P/E-8.26 USD
52-Week Change19.41 USD
Beta1.67 USD

Tandem Diabetes Care designs, develops, and commercializes advanced technology solutions for insulin-dependent diabetes management worldwide. The company's flagship products are the t:slim X2 insulin pump and the Tandem Mobi automated insulin delivery system, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology that helps optimize blood glucose levels. These durable insulin pumps work alongside continuous glucose monitoring systems, including integration with Abbott's FreeStyle Libre 3 Plus sensor. Tandem also manufactures disposable products such as infusion sets and cartridges for insulin storage and delivery. Nearly three-quarters of revenue derives from the United States, with the remainder primarily from other developed nations. The company serves individual patients with insulin-dependent diabetes across multiple distribution channels, including direct sales, pharmacy partnerships, and healthcare providers. Founded in 2006 and headquartered in San Diego, California, Tandem operates as a global leader in automated insulin delivery technology.

Industry

Medical Devices

Healthcare sector · United States

Stories

Structural patterns identified in Tandem Diabetes Care Inc.

No stories identified yet.

Key Metrics

Market Capitalization
1.71BUSD
NormalMar 24, 2026
Trailing P/E
-8.26USD
ExtremeMar 24, 2026
Revenue (TTM)
1.01BUSD
NormalMar 24, 2026
Profit Margin
-20.17%
NormalMar 24, 2026
Beta
1.67USD
NormalMar 24, 2026
52-Week Change
19.41USD
ExtremeMar 24, 2026

This company does not currently pay dividends.

Valuation9
Market Capitalization
1.71BUSD
NormalMar 24, 2026
Enterprise Value
1.85BUSD
NormalMar 24, 2026
Trailing P/E
-8.26USD
ExtremeMar 24, 2026
Forward P/E
-1.01KUSD
ExtremeMar 24, 2026
PEG Ratio
0.0413USD
NormalMar 24, 2026
Price to Sales (TTM)
1.67USD
NormalMar 24, 2026
Price to Book (MRQ)
10.92USD
NormalMar 24, 2026
Enterprise to Revenue
1.83USD
NormalMar 24, 2026
Enterprise to EBITDA
-30.64USD
ExtremeMar 24, 2026
Profitability & Growth16
Gross Margin
57.67%
NormalMar 24, 2026
Profit Margin
-20.17%
NormalMar 24, 2026
Operating Margin
2.86%
NormalMar 24, 2026
Return on Assets (TTM)
-0.0528USD
NormalMar 24, 2026
Return on Equity (TTM)
-0.9788USD
BelowNormalMar 24, 2026
Revenue (TTM)
1.01BUSD
NormalMar 24, 2026
Revenue per Share (TTM)
15.08USD
NormalMar 24, 2026
Quarterly Revenue Growth
0.0270USD
NormalMar 24, 2026
Gross Profit (TTM)
546.01MUSD
NormalMar 24, 2026
EBITDA
-60.46MUSD
ExtremeMar 24, 2026
Net Income (TTM)
-204.71MUSD
NormalMar 24, 2026
Operating Cash Flow (TTM)
-9.72MUSD
NormalMar 24, 2026
Levered Free Cash Flow (TTM)
-44.73MUSD
NormalMar 24, 2026
Trailing Annual Dividend Rate
0.00USD
NormalMar 24, 2026
Trailing Annual Dividend Yield
0.00%
NormalMar 24, 2026
Payout Ratio
0.00USD
NormalMar 24, 2026
Financial Strength13
Shares Outstanding
68.29MShares
NormalMar 24, 2026
Float Shares
62.59MUSD
NormalMar 24, 2026
Shares Short
9.76MShares
NormalMar 24, 2026
Short Ratio
3.89USD
NormalMar 24, 2026
Short % of Shares Outstanding
0.1972USD
NormalMar 24, 2026
% Held by Insiders
0.0101USD
NormalMar 24, 2026
% Held by Institutions
1.13USD
AboveNormalMar 24, 2026
Total Cash (MRQ)
292.67MUSD
NormalMar 24, 2026
Total Cash per Share (MRQ)
4.28USD
NormalMar 24, 2026
Total Debt (MRQ)
449.38MUSD
NormalMar 24, 2026
Total Debt to Equity (MRQ)
289.60USD
ExtremeMar 24, 2026
Current Ratio (MRQ)
2.55USD
NormalMar 24, 2026
Book Value per Share (MRQ)
2.27USD
NormalMar 24, 2026
Market & Technical9
52-Week Low
9.98USD
NormalMar 24, 2026
52-Week High
29.65USD
NormalMar 24, 2026
52-Week Change
19.41USD
ExtremeMar 24, 2026
Beta
1.67USD
NormalMar 24, 2026
50-Day MA
21.55USD
NormalMar 24, 2026
200-Day MA
17.77USD
NormalMar 24, 2026
Avg 10-Day Volume
2.09MUSD
NormalMar 24, 2026
Avg 30-Day Volume
2.61MUSD
NormalMar 24, 2026
Diluted EPS (TTM)
-3.04USD
NormalMar 24, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Medical Devices Supply Chain

The medical devices supply chain is shaped by three structural constraints that most manufacturing industries do not face: a regulatory classification cascade where risk level determines the years of validation required before a product can be sold, sterilization and biocompatibility requirements that restrict which materials and processes are permitted, and installed base dependency where hospitals commit to ecosystems that cannot be switched without replacing training, consumables, and data infrastructure.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.